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Background: Detection of epidermal growth factor receptor
(EGFR) mutations in advanced non-small cell lung cancer (NSCLC)
patients has relied on DNA purification from biopsies, amplification,
and sequencing. However, the number of tumor cells in a sample is
often insufficient for EGFR assessment.
Methods:We prospectively screened 1380 NSCLC patients for EGFR
mutations but found that 268 were not evaluable because of insufficient
tumor tissue. We therefore developed and validated a method of
detecting EGFR mutations in these samples. Tumor cells were micro-
dissected into polymerase chain reaction buffer and amplified. EGFR
mutations were detected by length analysis of fluorescently labeled
polymerase chain reaction products and TaqMan assay.
Results: We determined EGFR status in 217 (81%) of the 268
primary NSCLC samples not evaluable in our original study—fresh
and paraffin-embedded with less than 150 cells. Exon 19 deletions
were detected in 11.5% of patients and exon 21 L858R mutations in
5.5%. In addition, the exon 20 T790M mutation was detected in 6 of
15 (40%) patients at the time of progression to erlotinib. The
primary, sensitive mutation was present in all tumor cells, whereas
the T790M mutation was absent in some groups.
Conclusions: The method presented here eliminates the need for
DNA purification and allows for detection of EGFR mutations in
samples containing as few as eight cancer cells.
Key Words: Cytologic samples, EGFR mutations, erlotinib, Non-
small cell lung cancer, T790M.
(J Thorac Oncol. 2008;3: 1224–1235)
Mutations in the tyrosine kinase (TK) domain of the epi-dermal growth factor receptor (EGFR) have been identi-
fied as a cause of non-small cell lung cancer (NSCLC).1–5 The
most common oncogenic mutations are small in-frame dele-
tions in exon 19 and a point mutation (L858R) in exon 21.
These mutations likely cause constitutive activation of the
kinase6 and confer dramatic sensitivity to TK inhibitors
(TKIs) gefitinib and erlotinib.7,8 Clinically, the efficacy of
these TKIs has been demonstrated in numerous studies,9–13
and clinical trials of first-line gefitinib13 and erlotinib14 are
being carried out in patients whose tumors harbor EGFR
mutations. Unfortunately, the effect of TKIs is limited in time
because of the emergence of drug resistance. A second
mutation, a substitution T790M in exon 20,15–17 appears in
about half of all patients with acquired resistance to TKIs.18,19
However, the T790M kinase remains sensitive to irreversible
inhibitors.16,17,20–24
Screening of EGFR mutations, both for selecting
patients for treatment with TKIs and for detecting the
resistance mutation, is thus extremely important. However,
at present, the most common method of mutation detec-
tion—involving DNA purification from the whole tumor
sample, polymerase chain reaction (PCR)-based amplifi-
cation, and sequencing—has several limitations, the most
important of which is the need for large-sized samples.
Most of stage IV NSCLC patients have limited tumor
tissue available from biopsies, and the number of cells
present is often insufficient for DNA purification. In addi-
tion, cytologic samples—such as fine-needle biopsies,
bronchoalveolar aspirates, bronchoalveolar lavages, pleu-
ral effusions, and sputa—are frequently used to diagnose
NSCLC and may constitute the only available sample.
New methods are therefore required to detect EGFR mu-
tations in biopsies with a limited number of tumor cells
and in cytologic specimens.
A second drawback of sequencing techniques is that
the total DNA needs to contain a large proportion of
mutant DNA, which does not occur in many samples
containing only a small fraction of tumor cells. Sensitive
assays are currently being developed to detect mutations in
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samples containing less than 10% of mutant DNA.25–31
However, most of these assays also have limitations: they
require fresh-frozen tumor tissue samples, a large number
of cells, or refined molecular biology techniques.
In the present study, we have developed and vali-
dated a method to detect EGFR mutations that can be
applied to all types of samples: fresh or paraffin-embedded
biopsies and cytologic specimens. With this method,
EGFR mutations can be detected in samples containing as
few as eight cancer cells, in microscopic areas of the
tumors, and in separate clumps of cancer cells within
cytologic specimens.
MATERIALS AND METHODS
Cell Culture
The PC-9 lung tumor cell line cell line was kindly
provided by Roche (Basel, Switzerland); the H1975 cell
line was purchased from the American Type Culture Col-
lection (Manassas, VA). All tissue culture materials were
obtained from Biologic Industries (Kibbutz Beit Haemek,
Israel) or Invitrogen (Paisley, Scotland, United Kingdom).
Clinical Samples and Microdissection of Tumor
Cells
A total of 268 NSCLC samples were analyzed: 223
paraffin-embedded and 45 fresh specimens. All 268 samples
contained less than 150 tumor cells and had previously been
deemed unevaluable for EGFR mutations in our laboratory.
Paraffin-embedded samples and slides were obtained
by standard procedures.11 Fresh specimens were extended
over an appropriate slide, fixed with 96% ethyl-alcohol and
stained with Harris hematoxylin for 1 minute. Once the
specimen was stained and rinsed in running water, a cover
slide was placed over it to observe and mark the presence of
malignant cells. Later, the cover slide could be removed and
the sample kept in this stage for not more than 2 or 3 days.
Tumor cells were identified by a pathologist.
For both fresh and paraffin-embedded samples, tumor
cells (8–150) were captured by laser microdissection (Palm,
Oberlensheim, Germany) into 10 l of PCR buffer (Ecogen,
Barcelona, Spain) plus proteinase K and incubated 4 hours to
overnight at 60°C. Proteinase was inactivated at 95°C for 10
minutes, and the cell extract submitted to PCR. DNA from
the cell line PC-9 was used as a mutated control for exon 19,
and wild-type control for exons 20 and 21. DNA from the
H1975 cell line was used as a wild-type control for exon 19,
and mutated control for exons 21/20.
PCR Analysis and EGFR Gene Sequencing
Exons 19, 20, and 21 of the EGFR gene were
amplified by a nested PCR as described.11 Primers were as
follows: exon 19 (first PCR, forward 5-GCAATAT-
CAGCCTTAGGTGCGGCTC-3, and reverse 5-CATA-
GAAAGTGAACATTTAGGATGTG-3; second PCR, forward
5-GTGCATCGCTGGTAACATCC-3 and reverse 5-TG-
TGGAGATGAGCAGGGTCT-3); exon 21 (first PCR,
forward 5-CTAACGTTCGCCAGCCATAAGTCC-3 and
reverse 5-GCTGCGAGCTCACCCAGAATGTCTGG-3,
second PCR, forward 5-GCTCAGAGCCTGGCATGAA-3
and reverse 5-CATCCTCCCCTGCATGTGT-3); exon 20
(first PCR, forward 5-ACTTCACAGCCCTGCGTAAAC-3
and reverse 5-ATGGGACAGGCACTGATTTGT-3; nested
PCR, forward 5-AGGCAGCCGAAGGGCA-3 and reverse
5-CCTCACCTCCACCGTGCA-3). The first PCR was per-
formed in 50-l volumes adding 2 l of sample, 2 U of
Ecotaq Polimerase (Ecogen, Barcelona, Spain), 7.5 l of
PCR buffer 10, 250 M dNTPs, 3.5 mM MgCl2, and 0.5
pmol of each primer. Amplification was as follows: 25 cycles
of 30 seconds at 94°C, 30 seconds at 64°C, and 1 minute at
72°C (exons 19 and 21), or 35 cycles of 30 seconds at 94°C,
30 seconds at 58°C, and 1 minute at 72°C (exon 20). For the
nested PCR, amplification was done using 2 l (for exons 19
and 20) or 4 l (for exon 21) of first PCR product, 1.25 U of
Ecotaq Polymerase, 250 M dNTPs, 1.5 mM MgCl2, and 0.5
pmol of each primer. Cycles were as follows: for exon 19, 35
cycles of 30 seconds at 94°C, 30 seconds at 64°C, and 1
minute at 72°C; for exon 21, 40 cycles of 30 seconds at 94°C,
30 seconds at 64°C, and 1 minute at 72°C; and for exon 21,
20 cycles of 30 seconds at 94°C, 30 seconds at 59°C, and 1
minute at 72°C.
PCR products were visualized on a 2% agarose gel.
Sequencing was performed using forward and reverse nested
primers with the ABI Prism 3100 DNA Analyzer (Applied
Biosystems, Foster City, CA).
Length Analysis of Fluorescently Labeled PCR
Products for EGFR Deletions in Exon 19
The products of the first PCR for exon 19 were ampli-
fied with the following primers: forward 5-ACTCTGGATC-
CCAGAAGGTGAG-3 and reverse 5-FAM-CCACACAG-
CAAAGCAGAAACTC-3. Amplification was done for 32
cycles (30 seconds at 94°C, 30 seconds at 58°C, and 1 minute
at 72°C) in 50-l volumes using 1 U of Ecotaq Polymerase,
250 M dNTPs, 1 mM MgCl2, and 0.5 pmol of each primer.
One microliter of a 1/50 to 1/200 dilution of each PCR
product was mixed with 0.5 l of size standard (Applied
Biosystems) and denatured in 9 l formamide at 90°C for 5
minutes. Separation was done with a four-color laser-induced
fluorescence capillary electrophoresis system (ABI Prism
3130 Genetic Analyzer, Applied Biosystems). The collected
data were evaluated with the GeneScan Analysis Software
(Applera, Norwalk, CT).
TaqMan Assay for EGFR Mutation in Exons 20
(T790M) and 21 (L858R)
The products of the first PCR for exons 20 and 21 were
analyzed by TaqMan. Primers and probes were as follows: exon
21 (forward primer, 5-AACACCGCAGCATGTCAAGA-3,
reverse primer 5-TTCTCTTCCGCACCCAGC-3; probes
5-FAM-CAGATTTTGGGCGGGCCAAAC-TAMRA-3; and
5-VIC-TCACAGATTTTGGGCTGGCCAAAC-TAMRA-3)
and exon 20 (forward primer, 5-AGGCAGCCGAAGGGCA-
3, reverse primer 5-CCTCACCTCCACCGTGCA-3; probes
5 VIC-TGAGCTGCGTGATGA-MGB-3; and 5-FAM-
TGAGCTGCATGATGA-MGB-3). Amplification was per-
formed in 25-l volumes using 2 l of first PCR product, 12.5
l of Ampli Taq Gold PCR Master Mix (Applied Biosystems),
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0.6 pmol of each primer and 0.2 pmol of probes. Samples were
submitted to 40 cycles of 15 seconds at 94°C and 1 minute at
60°C in an Applied Biosystems 7000 real-time cycler.
RESULTS
The method described here involves 3 steps: (1) direct
microdissection of tumor cells into PCR buffer; (2) a first round
of PCR for each EGFR exon; and (3) determination of EGFR status
by length analysis (exon 19) or TaqManAssay (exons 20, 21) using
the first PCR product as a template. This method was comple-
mented by further analysis using nested PCR and sequencing.
To evaluate the sensitivity of our assay, we used seri-
ally diluted genomic DNA from the cell lines PC-9 (harbor-
ing a deletion in exon 19) and H1975 (harboring both the
T790M and the L858R mutations). Ten pg of DNA were
successfully amplified and the corresponding mutations de-
tected. Finally, we trypsinized PC9 and H1975 tumor cells in
culture, extended them on a slide and microdissected them in
different quantities (1–20 cells). Four tumor cells were suf-
ficient to determine EGFR mutation status (supplementary
Figure S1).
Exon 19 Deletion and L858R Mutation
From May 2006 to December 2007, we prospectively
screened EGFR mutations in 1380 NSCLC patients for the
purpose of customizing erlotinib treatment. Of these, 268
were not evaluable with the standard procedures used (DNA
extraction with phenol:chloroform, followed by ethanol pre-
cipitation, PCR, and sequencing of PCR products) because of
insufficient tumor tissue (fewer than 150 tumor cells). In the
present study, we have reexamined these 268 samples (Table
1), that included: fresh and paraffin-embedded biopsies (192
samples), cytologic specimens from bronchoalveolar lavages
and aspirates (9 samples), fine-needle aspirates (31 samples),
pleural and pericardial fluids (33 samples), and others (3
samples). EGFR mutation status was successfully determined
in 217 (81%) of the 268 samples: 45 of 45 fresh and 172 of
223 paraffin-embedded specimens (Table 1). Although sam-
ples with as little as eight tumor cells were successfully
amplified, a few containing as many as 100 tumor cells were
not, because of poor quality.
These results were then validated by sequencing. In 187
of the 217 samples successfully analyzed, exon 19 deletion
was assessed by nested PCR followed by sequencing, and the
results were identical to those obtained by length analysis. In
170 of the 217 samples, the L858R mutation was assessed by
sequencing, and the results were identical to those obtained
with the TaqMan assay. The method was further validated in
30 additional NSCLC tumor samples analyzed by standard
procedures in a previous study.32 The results obtained with
our method were identical to the original results.
EGFR mutations were detected in 37 of the 217 sam-
ples successfully analyzed (17%). Exon 19 deletions were
found in 11.5% of samples, and L858R mutations in 5.5%
(Table 2 and Figure 1). The frequency of mutations was
higher in females, never-smokers, and adenocarcinoma pa-
tients (Table 2). Eighteen exon 19 deletions were delE746-
A750, four were delL747-S752 (two of them with an addi-
tional P753S, and one with P753SA755S), one was
delL747-E749  A750P and one was delA750-E758 plus
two additional silent point mutations. Finally, a case with a
single somatic point mutation (A750P) was also detected.
Eleven samples had the L858R mutation and only one had the
L861Q mutation at exon 21.
Thirty-five patients with EGFR mutations were treated
with erlotinib (Table 3). Survival data is available for 20 of
them. Overall median survival has not been reached; and
some have obtained dramatic, long lasting responses (Figure
2). Of 14 patients evaluable for response, two attained com-
TABLE 1. Baseline Assessment of EGFR Mutations at
Exons 19 and 21 in Samples with Fewer Than 150 Tumor
Cells
Type of Sample
No. of
Samples
EGFR Status
Determined (%)
No. of Tumor Cells
per Sample (range)
Paraffin-embedded 223 172 (77) 8–150
Ctologies 32 28 (88)
Biopsies 191 144 (74)
Fresh samples 45 45 (100) 25–150
Cytologies 44 44 (100)
Biopsies 1 1 (100)
Total 268 217 (81)
TABLE 2. Patient Characteristics. Percentages Refer to the
No. of Patients with Complete Data Recorded
Patients with
Mutations
Patients without
Mutations
N Percent N Percent
Total number 37 180
Patients with complete data
recorded
37 145
Exon 19 25 11.5 — —
Deletion 24
Point mutation 1
Exon 21 12 5.5 — —
L858R 11
L861Q 1
Gender
Male 10 27 87 60
Female 27 73 58 40
Age, median (range) 62.3 (39–89) 65.0 (35–89)
Smoking history
Current 7 19 36 25
Ex 4 11 24 17
Never 24 65 66 45
Not reported 2 5 19 13
Histology
Adenocarcinoma 34 92 118 81
Undifferentiated 1 3 16 11
Other 2 5 11 8
Stage
I-II 2 5 8 6
III–IV 34 92 128 88
Not reported 1 3 9 6
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FIGURE 1. A, Example of length analysis for a wild-type (top panel) and a mutated patient (bottom panel) for exon 19
of EGFR. The peaks corresponding to the samples are represented in blue, the molecular weight markers (75, 100, 139,
150, and 160 bp) in orange. The mutated patient harbors a 15-bp deletion. B, Example of Taqman assay for a subset of
patients. The two green triangles correspond to the H1975 cell line and to a tumor harboring the L858R mutation. The
red circles correspond to the PC-9 cell line and to several wild-type tumors. The gray squares are negative and extraction
controls.
TABLE 3. Clinical Outcome of Patients with EGFR Mutations Treated with Erlotinib
Patient EGFR Mutation Treatment Started (date) Response to Erlotinib Survival Status
1 A750P June 30, 2006 NE Da (after 1 mo)
2 delE746-A750 October 26, 2006 PR A
3 L858R November 15, 2006 SD A
4 delE746-A750 April 1, 2007 PR A
5 L858R February 08, 2007 NE A
6 L861R December 5, 2006 PD D (after 1 mo)
7 delE746-A750 January 24, 2007 SD A
8 L858R February 20, 2007 SD A
9 delE746-A750 April 11, 2007 PR A
10 delE746-A750 August 18, 2007 NE A
11 delL747-E749  A750P May 24, 2007 CR A
12 delE746-A750 May 23, 2007 SD A
13 delE746-A750 December 8, 2006 PR A
14 L858R June 29, 2007 NE A
15 delE746-A750 July 30, 2007 NE A
16 delE746-A750 July 1, 2007 NE A
17 delE746-A750 October 1, 2007 SD A
18 delE746-A750 February 12, 2007 CR A
19 delE746-A750 April 15, 2007 PR A
20 L858R June 8, 2007 SD D (after 6 mo)
a The cause of death was a bacterial infection in the lungs.
NE, not evaluated; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; D, dead; A, alive.
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plete and five partial response, six stable disease, and one
progressive disease. All responses were observed in patients
with exon 19 deletions, whereas all L858R patients had stable
disease. Progressive disease was observed in the only patient
with the rare L861Q mutation. In contrast, the patient har-
boring the exon 19 delL747-E749  A750P attained a com-
plete response.
EGFR T790M Mutations in Patients Progressing
to Erlotinib
EGFR T790M mutation status was evaluated in 15
patients at the time of progression in cytologic specimens or
tumor samples obtained from rebiopsy. The T790M mutation
was detected in six patients (40%), a frequency within the
range reported in other studies, that is also around 40
to50%.33,34 Exons 19 and 21 were also analyzed; the mutation
detected in the primary tumor sample was also present in the
rebiopsy or recytology sample in all 15 cases. The T790M
mutation was more frequent in patients with exon 19 dele-
tions (five of nine) than in those with the L858R mutation
(one of six).
In 7 of the 15 patients progressing to erlotinib, the
size and cellularity of the samples were sufficient to
microdissect and analyze separate areas of the tumor
sample or clumps of tumor cells in the cytologic specimens
(Table 4). In all seven cases, the primary exon 19 deletions
or exon 21 L858R mutations were detected in all the cells
analyzed. The T790M mutation was found in only two
patients (Table 4, patients A and E), where it was detected
in many but not all of the cells. In patient A, four
microscopic areas of the tumor sample (rebiopsy at the site
of progression) were analyzed; the primary exon 19 dele-
tion was detected in all four areas, but the T790M mutation
was detected in only three (Figure 3). In patient E, three
clumps of tumor cells from pleural fluid and three micro-
scopic areas of the rebiopsy at the site of progression were
studied; the primary exon 19 deletion was present in all
areas, but the T790M mutation could not be detected in
two separate groups of cells, one from the rebiopsy and the
other from the pleural fluid.
DISCUSSION
Since the discovery of its clinical relevance, the detec-
tion of EGFR mutations has relied on direct sequencing of
PCR products, a method still widely used. However, there is
a growing interest in new methods that can overcome some of
its drawbacks. Most of these novel methods include steps
designed to amplify mutant DNA when a large amount of
wild-type, nontumor DNA is present or to avoid sequencing
and standard PCR to accelerate the assay. For example, the
SMart-Amplification Process33 can detect a mutation in
mixed-cell populations in just 30 minutes. However, this
method has only been tested in fresh biopsies containing 5 mg
of tissue, a kind of sample rarely available in advanced
NSCLC. The mutant-enriched PCR27 and the Scorpions Am-
plified Refractory Mutation System28 have been used in other
types of fresh samples but not in paraffin-embedded speci-
mens, where successful EGFR analysis is more difficult.34 In
addition, these methods include several DNA purification
steps (phenol: chloroform extraction, ethanol precipitation)
that prevent their use in samples containing a limited number
of cells. Finally, the loop-hybrid mobility shift assay30 and
the SURVEYOR analysis26 have been used in paraffin-
FIGURE 2. Example of response to
erlotinib (patient 13 in Table 3) harbor-
ing exon 19 delL746–A750, detected in
pleural fluid. Top panel: CT scan prior
to erlotinib treatment (A) and after 1
year of erlotinib treatment (B). Bottom
panel: plain chest radiograph before
erlotinib treatment (C) and after 1 year
of erlotinib treatment (D).
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embedded samples, but they also require prior DNA purifi-
cation.
In this study, we have developed and validated a
method to determine EGFR status in samples containing less
than 150 tumor cells that can be used in both fresh and
paraffin-embedded biopsies and cytologic samples. In our
experience, at least one third of NSCLC primary diagnoses
are made solely on the basis of cytologic specimens, where
the number of tumor cells is very limited. In addition, even
when a biopsy is available, the number of tumor cells is less
than 150 in more than 15% of samples. Our method thus
significantly increases the number of NSCLC patients that
can be screened for EGFR mutations.
This method is based on microdissection of tumor cells
directly into PCR buffer, followed by amplification and
determination of EGFR status by length analysis of fluores-
cently-labeled products (exon 19 deletion) or TaqMan assay
(exon 20 T790M and exon 21 L858R). This method can be
applied to any other exon, however, our focus was on dele-
tions in exon 19 and the L858R in exon 21, because they
account for the great majority of sensitive EGFR mutations.
Because there is no need for prior DNA purification,
our method is highly sensitive; EGFR mutations at exons 19,
20, and 21 can be detected in samples containing as few as
eight cells (in 10 l of buffer), approximately 5 pg of DNA
per microliter of crude extract. This compares favorably to
the sensitivity of the SMart-Amplification Process (210 pg, or
30 copies, of mutant, purified DNA per microliter) or the
Scorpions Amplified Refractory Mutation System (100 pg
of purified DNA per microliter). Other methods are even less
sensitive; mutant enriched PCR requires 5 to 100 ng of DNA,
the loop-hybrid mobility shift assay needs two complete
10-m sections of a paraffin-embedded biopsy, and the
SURVEYOR assay requires ten 5-m sections or four 10-m
sections of a paraffin-embedded biopsy to obtain 3 to 30 g
of DNA. Finally, slide scrape with no prior purification
requires at least 10 mm2 of tumor area to obtain a minimum
of 79 ng DNA per microliter.29
The method described here also allows for analysis of
separate, microscopic groups of cells within a tumor mass
and clumps of cells in cytologic specimens. We have used it
successfully to analyze more than three groups of cells in six
TABLE 4. Patients with Three or More Groups of Tumor Cells Analyzed
Patient Primary Mutation
Groups of Tumor
Cells Analyzed
Exon 19/21
Status
Exon 20
Status
A Exon 19 (delE746-A750) PB1 delE746-A750 wt
PB2 delE746-A750 T790M
PB3 delE746-A750 T790M
PB4 delE746-A750 T790M
B Exon 19 (delE746-A750) PB1 delE746-A750 wt
PB2 delE746-A750 wt
PB3 delE746-A750 wt
PB4 delE746-A750 wt
C Exon 19 (delE746-A750) PB1 delE746-A750 wt
PB2 delE746-A750 wt
PB3 delE746-A750 wt
PB4 delE746-A750 wt
PB5 delE746-A750 wt
D Exon 21 (L858R) FP1 L858R wt
PB1 L858R wt
PB2 L858R wt
PB3 L858R wt
E Exon 19 (delE746-A750) PB1 delE746-A750 wt
PB2 delE746-A750 T790M
PB3 delE746-A750 T790M
PE1 delE746-A750 T790M
PE2 delE746-A750 T790M
PE3 delE746-A750 wt
F Exon 21 (L858R) CE1 L858R wt
CE2 L858R wt
CE3 L858R wt
CE4 L858R wt
G Exon 21 (L858R) PP1 L858R wt
PP2 L858R wt
PP3 L858R wt
PB, paraffin-embedded biopsy; FP, fresh biopsy; PE, fresh pleural fluid; CE, fresh pericardial fluid; PP,
paraffin-embedded pleural fluid; wt, wild-type.
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samples from patients progressing to erlotinib. In all cases,
the primary mutation (in exon 19 or 21) was present in all the
groups of tumor cells.
Although the primary mutation (exon 19 deletion or L858R)
was present in all the groups of tumor cells analyzed, the T790M
resistance mutation was not. In some tumors, the T790M mutation
seems to be underrepresented relative to the total number of EGFR
alleles,18 leading to the speculation that it might be present in only
a subset of resistant cancer cells,35,36 thus increasing the importance
of a method able to detect mutations in a small number of cells.
In conclusion, we have developed and validated a
method to detect EGFR mutations that can be applied to fresh
or paraffin-embedded biopsies and cytologic specimens con-
taining as few as eight cancer cells, thus widening the range
of lung tumor patients that can be tested for EGFR mutations.
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FIGURE S1. Sensitivity of the assay: Serially diluted genomic DNA from the cell lines PC-9 (harboring a deletion in exon 19)
and H1975 (harboring both the T790M and the L858R mutations) was analyzed (A and C). Ten picogram of DNA were suc-
cessfully amplified and the corresponding mutations detected. We also trypsinized tumor cells in culture, extended them on a
slide and microdissected them in different quantities. Four tumor cells were sufficient to determine EGFR mutation status (B
and D).
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FIGURE S1. (Continued).
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FIGURE S1. (Continued).
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FIGURE S1. (Continued).
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